#KVAERNER #MASA #YARDS
allgraph.ro/related-sear...
#JOHN #HERN
aepiot.ro/related-sear...
#TROFINETIDE
aepiot.com/related-sear...
aepiot.ro
allgraph.ro/related-sear...
#JOHN #HERN
aepiot.ro/related-sear...
#TROFINETIDE
aepiot.com/related-sear...
aepiot.ro
Search Related Reports
Search Related Reports - aéPiot: Independent SEMANTIC Web 4.0 Infrastructure (Est. 2009). High-density Functional Semantic Connectivity with 100/100 Trust Score and Verified Kaspersky Integrity across...
allgraph.ro
September 8, 2026 at 4:09 AM
Acadia: 'Trofinetide, primo e unico con questa indicazione'
Sindrome di Rett, ok in Europa a trattamento per sintomi neurocomportamentali
ebx.sh
September 2, 2026 at 2:14 AM
Acadia: 'Trofinetide, primo e unico con questa indicazione'
Sindrome di Rett, ok in Europa a trattamento per sintomi neurocomportamentali
Sindrome di Rett, ok in Europa a trattamento per sintomi neurocomportamentali
(Adnkronos) - La Commissione europea (Ce) ha concesso l’autorizzazione all’immissione in commercio per trofinetide “nel trattamento dei sintomi neurocomportamentali della sindrome di Rett in pazienti adulti e pediatrici di età pari o superiore a cinque anni. Il farmaco è il primo e unico trattamento
www.shmag.it
September 1, 2026 at 9:22 AM
Sindrome di Rett, ok in Europa a trattamento per sintomi neurocomportamentali
EC authorised Daybu today — Rett symptoms from age 5. Commission MA, not a CHMP opinion. National HTA still open.
https://europepharmatoday.com/news/ec-daybu-trofinetide-rett-syndrome-august-2026?utm_source=bluesky&utm_medium=social&utm_campaign=ec-daybu-trofinetide-rett-syndrome-august-2026
https://europepharmatoday.com/news/ec-daybu-trofinetide-rett-syndrome-august-2026?utm_source=bluesky&utm_medium=social&utm_campaign=ec-daybu-trofinetide-rett-syndrome-august-2026
August 24, 2026 at 5:40 PM
EC authorised Daybu today — Rett symptoms from age 5. Commission MA, not a CHMP opinion. National HTA still open.
https://europepharmatoday.com/news/ec-daybu-trofinetide-rett-syndrome-august-2026?utm_source=bluesky&utm_medium=social&utm_campaign=ec-daybu-trofinetide-rett-syndrome-august-2026
https://europepharmatoday.com/news/ec-daybu-trofinetide-rett-syndrome-august-2026?utm_source=bluesky&utm_medium=social&utm_campaign=ec-daybu-trofinetide-rett-syndrome-august-2026
EC greenlights Acadia’s DAYBU for Rett Syndrome in Europe
https://www.byteseu.com/2303454/
Acadia Pharmaceuticals has secured European Commission approval for DAYBU (trofinetide), opening the door to the first treatment authorised for the neurobehavioural symptoms of Rett syndrome in the …
https://www.byteseu.com/2303454/
Acadia Pharmaceuticals has secured European Commission approval for DAYBU (trofinetide), opening the door to the first treatment authorised for the neurobehavioural symptoms of Rett syndrome in the …
EC greenlights Acadia’s DAYBU for Rett Syndrome in Europe - Bytes Europe
Acadia Pharmaceuticals has secured European Commission approval for DAYBU (trofinetide), opening the door to the first treatment authorised for the
www.byteseu.com
August 24, 2026 at 12:52 PM
EC greenlights Acadia’s DAYBU for Rett Syndrome in Europe
https://www.byteseu.com/2303454/
Acadia Pharmaceuticals has secured European Commission approval for DAYBU (trofinetide), opening the door to the first treatment authorised for the neurobehavioural symptoms of Rett syndrome in the …
https://www.byteseu.com/2303454/
Acadia Pharmaceuticals has secured European Commission approval for DAYBU (trofinetide), opening the door to the first treatment authorised for the neurobehavioural symptoms of Rett syndrome in the …
#AcadiaPharmaceuticals has secured #EuropeanCommission approval for #DAYBU (trofinetide), opening the door to the first treatment authorised for the #neurobehavioural symptoms of #Rettsyndrome in the #EuropeanUnion.
pharmaphorum.com/news/ec-gree...
pharmaphorum.com/news/ec-gree...
EC greenlights Acadia’s DAYBU for Rett Syndrome in Europe
Acadia Pharmaceuticals has secured EC approval for DAYBU (trofinetide) for the neurobehavioural symptoms of Rett syndrome in the EU.
pharmaphorum.com
August 24, 2026 at 12:20 PM
#AcadiaPharmaceuticals has secured #EuropeanCommission approval for #DAYBU (trofinetide), opening the door to the first treatment authorised for the #neurobehavioural symptoms of #Rettsyndrome in the #EuropeanUnion.
pharmaphorum.com/news/ec-gree...
pharmaphorum.com/news/ec-gree...
🟢 #$ACAD — Regulatory Designation
CHMP Positive Opinion Recommending EU Marketing Authorization
The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for DAYBUE (trofinetide) for neurobeh…
https://biostock.app/symbols/ACAD
CHMP Positive Opinion Recommending EU Marketing Authorization
The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for DAYBUE (trofinetide) for neurobeh…
https://biostock.app/symbols/ACAD
August 4, 2026 at 8:55 PM
🟢 #$ACAD — Regulatory Designation
CHMP Positive Opinion Recommending EU Marketing Authorization
The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for DAYBUE (trofinetide) for neurobeh…
https://biostock.app/symbols/ACAD
CHMP Positive Opinion Recommending EU Marketing Authorization
The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for DAYBUE (trofinetide) for neurobeh…
https://biostock.app/symbols/ACAD
Mapping Trofinetide Polypharmacology in Rett Syndrome: A Multi‐Stage Computational Analysis https://onlinelibrary.wiley.com/doi/10.1002/jcc.70468?af=R
August 1, 2026 at 12:31 AM
Mapping Trofinetide Polypharmacology in Rett Syndrome: A Multi‐Stage Computational Analysis https://onlinelibrary.wiley.com/doi/10.1002/jcc.70468?af=R
Treatment centers on trofinetide — the first and only FDA-approved drug for Rett, approved in March 2023 for ages 2+. It's a lab-made analog of a small IGF-1 fragment; the exact mechanism still isn't fully known, but it showed a modest benefit in the Phase 3 LAVENDER trial.
July 8, 2026 at 3:34 PM
Treatment centers on trofinetide — the first and only FDA-approved drug for Rett, approved in March 2023 for ages 2+. It's a lab-made analog of a small IGF-1 fragment; the exact mechanism still isn't fully known, but it showed a modest benefit in the Phase 3 LAVENDER trial.
trofinetide.
June 29, 2026 at 2:52 AM
trofinetide.
trofinetide.
June 29, 2026 at 2:51 AM
trofinetide.
On June 29, Reuters' Health Check column reported that Neuren Pharmaceuticals shares surged more than 30% after European regulators reversed course and approved the company's Rett syndrome therapy, trofinetide. The reversal cut through an otherwise macro-driven tape, where
June 29, 2026 at 2:50 AM
On June 29, Reuters' Health Check column reported that Neuren Pharmaceuticals shares surged more than 30% after European regulators reversed course and approved the company's Rett syndrome therapy, trofinetide. The reversal cut through an otherwise macro-driven tape, where
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
https://www.byteseu.com/2149231/
— European Commission decision expected in the coming months — If approved, DAYBU® would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union …
https://www.byteseu.com/2149231/
— European Commission decision expected in the coming months — If approved, DAYBU® would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union …
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP - Bytes Europe
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the
www.byteseu.com
June 29, 2026 at 2:00 AM
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
https://www.byteseu.com/2149231/
— European Commission decision expected in the coming months — If approved, DAYBU® would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union …
https://www.byteseu.com/2149231/
— European Commission decision expected in the coming months — If approved, DAYBU® would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union …
#$ACAD DAYBU (trofinetide) gets EU positive opinion for Rett syndrome; could become first approved treatment for symptoms in Europe. notreload.xyz/xy/acadia-da...
Acadia’s DAYBU Receives Positive CHMP Opinion for Rett Syndrome
Acadia’s DAYBU gets EU positive opinion for Rett syndrome; could become first approved treatment for symptoms in Europe.
notreload.xyz
June 26, 2026 at 11:49 AM
#$ACAD DAYBU (trofinetide) gets EU positive opinion for Rett syndrome; could become first approved treatment for symptoms in Europe. notreload.xyz/xy/acadia-da...
💵 #Forex
"— European Commission decision expected in the coming months — If approved, DAYBU® would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union SAN DIEGO — Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the…"
"— European Commission decision expected in the coming months — If approved, DAYBU® would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union SAN DIEGO — Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the…"
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
financialpost.com
June 26, 2026 at 11:21 AM
#ACAD DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
https://www.stocktitan.net/news/ACAD/daybu-trofinetide-recommended-for-approval-in-the-european-union-by-0dtztojjbdf0.html
https://www.stocktitan.net/news/ACAD/daybu-trofinetide-recommended-for-approval-in-the-european-union-by-0dtztojjbdf0.html
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
Acadia (Nasdaq: ACAD) announced that EMA’s CHMP adopted a positive opinion, after re-examination, recommending EU marketing authorization for DAYBU (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and children ≥5 years. If approved by the European Commission, DAYBU would be the first therapy for this indication across the EU and EEA, supported by Phase 3 LAVENDER data showing statistically significant, clinically meaningful improvements on RSBQ and CGI-I scales.
www.stocktitan.net
June 26, 2026 at 10:49 AM
#ACAD DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
https://www.stocktitan.net/news/ACAD/daybu-trofinetide-recommended-for-approval-in-the-european-union-by-0dtztojjbdf0.html
https://www.stocktitan.net/news/ACAD/daybu-trofinetide-recommended-for-approval-in-the-european-union-by-0dtztojjbdf0.html
Weekly review: trofinetide, genomic testing, and more | Contemporary Pediatrics - goo.gl/alerts/9q3WeU #GoogleAlerts
Weekly review: trofinetide, genomic testing, and more | Contemporary Pediatrics
Get caught up with Contemporary Pediatrics. This list helps you navigate our top stories from the week, all in one place.
goo.gl
April 13, 2026 at 6:22 AM
Weekly review: trofinetide, genomic testing, and more | Contemporary Pediatrics - goo.gl/alerts/9q3WeU #GoogleAlerts
#ACAD Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
https://www.stocktitan.net/news/ACAD/acadia-pharmaceuticals-announces-daybue-stix-trofinetide-is-now-pk6yynr2203j.html
https://www.stocktitan.net/news/ACAD/acadia-pharmaceuticals-announces-daybue-stix-trofinetide-is-now-pk6yynr2203j.html
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Inc. today announced DAYBUE ® STIX for oral solution, a dye- and preservative-free powder formulation of trofinetide, is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation, approved by the U.S. Food and Drug Administration in...
www.stocktitan.net
April 7, 2026 at 1:05 PM
#ACAD Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
https://www.stocktitan.net/news/ACAD/acadia-pharmaceuticals-announces-daybue-stix-trofinetide-is-now-pk6yynr2203j.html
https://www.stocktitan.net/news/ACAD/acadia-pharmaceuticals-announces-daybue-stix-trofinetide-is-now-pk6yynr2203j.html
EMA recommends refusal of Daybu in Rett syndrome after limited clinically meaningful effect
https://www.mattheneus.com/editorial/ema-daybu-trofinetide-refusal-rett-syndrome-clinical-meaningfulness-2026-03-10
#HTA #RegulatoryAffairs #HealthEconomics
https://www.mattheneus.com/editorial/ema-daybu-trofinetide-refusal-rett-syndrome-clinical-meaningfulness-2026-03-10
#HTA #RegulatoryAffairs #HealthEconomics
March 10, 2026 at 8:27 PM
EMA recommends refusal of Daybu in Rett syndrome after limited clinically meaningful effect
https://www.mattheneus.com/editorial/ema-daybu-trofinetide-refusal-rett-syndrome-clinical-meaningfulness-2026-03-10
#HTA #RegulatoryAffairs #HealthEconomics
https://www.mattheneus.com/editorial/ema-daybu-trofinetide-refusal-rett-syndrome-clinical-meaningfulness-2026-03-10
#HTA #RegulatoryAffairs #HealthEconomics